Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04068896 · ClinicalTrials.gov registry record · Phase 1
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
A Phase 1 study, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
NCT04068896: Completed Phase 1 study, sponsored by NGM Biopharmaceuticals.
NCT04068896 is a Phase 1 study that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 89 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04068896, a Phase 1 study, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
Study Summary
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
Primary Outcome
Number of Participants with NGM120/Placebo-Related Treatment Emergent Adverse Events
Interventions
- BIOLOGICAL NGM120 30mg
- BIOLOGICAL NGM120 100mg
- BIOLOGICAL NGM120 30mg with Gemcitabine and Abraxane
- BIOLOGICAL NGM120 100mg with Gemcitabine and Abraxane
- BIOLOGICAL NGM120 100mg Q3W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2019-10-16 |
| Est. Completion | 2024-01-08 |
| Phase | Phase 1 |
What the finished NCT04068896 record still lists
NCT04068896 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% higher).
The record links to 0 conditions, and to 5 interventions - of which NGM120 30mg is the first listed.
NCT04068896 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04068896 about?
NCT04068896 is a clinical study titled "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy". Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
What is the current status of trial NCT04068896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2019-10-16. Estimated completion is 2024-01-08.
What interventions are being tested in trial NCT04068896?
The interventions under investigation include: NGM120 30mg (BIOLOGICAL), NGM120 100mg (BIOLOGICAL), NGM120 30mg with Gemcitabine and Abraxane (BIOLOGICAL), NGM120 100mg with Gemcitabine and Abraxane (BIOLOGICAL), NGM120 100mg Q3W (BIOLOGICAL).
Who is sponsoring clinical trial NCT04068896?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04068896's enrollment target sits among peer trials
89 649th of 2000 higher than 1,351 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI